Derivative exercise or conversion — not an open-market buy.
Traded May 8, 2026 · Filed May 12, 2026
A board member of Bio-Techne sold $320K of Bio-Techne shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$320,386
Shares × reported transaction price
2 days after results of May 6, 2026, 96 days before results of Aug 12, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $48.36 on May 8, 2026, within 4% of its 52-week low, after an 8% drop over the previous 30 trading days
52-week range $46.66 (May 21, 2025) to $71.375 (Jan 21, 2026), 7% of the way up, from 251 adjusted closes. 30 trading days earlier: $52.70 on Mar 26, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +4.0% | -0.1% | +4.2% |
| 30 days | +20.3% | -0.1% | +20.4% |
| 90 days | +60.7% | +3.8% | +56.9% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
Derivative exercise or conversion — not an open-market buy.